{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:20:22Z","timestamp":1793866822044,"version":"4.6.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3520,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s13311-013-0244-z","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T10:10:47Z","timestamp":1387793447000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Treatment of Huntington's Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Samuel","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0244-z_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0244-z_bib2","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-013-0244-z_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.1172871","article-title":"Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity","volume":"324","author":"Subramaniam","year":"2009","journal-title":"Science"},{"key":"10.1007\/s13311-013-0244-z_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1523\/JNEUROSCI.4974-09.2010","article-title":"Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease","volume":"30","author":"Ribeiro","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0244-z_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neulet.2007.02.027","article-title":"Complex movement behavior and progression of Huntington's disease","volume":"416","author":"Andrich","year":"2007","journal-title":"Neurosci Lett"},{"issue":"Suppl. 5","key":"10.1007\/s13311-013-0244-z_bib6","first-page":"A204","article-title":"Functional decline due to chorea in Huntington's disease","volume":"62","author":"Frank","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib8","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","article-title":"Huntingtin aggregation and toxicity in Huntington's disease","volume":"361","author":"Bates","year":"2003","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0244-z_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0244-z_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-013-0244-z_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410310412","article-title":"Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease","volume":"31","author":"Albin","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib12","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0244-z_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0301-0082(99)00019-2","article-title":"The selective vulnerability of striatopallidal neurons","volume":"59","author":"Mitchell","year":"1999","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-013-0244-z_bib14","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1007\/s13311-013-0244-z_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.410420213","article-title":"Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease","volume":"42","author":"Augood","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib16","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","article-title":"Thalamic metabolism and symptom onset in preclinical Huntington's disease","volume":"130","author":"Feigin","year":"2007","journal-title":"Brain"},{"key":"10.1007\/s13311-013-0244-z_bib17","first-page":"2353","article-title":"Huntington's disease progression","volume":"122","author":"Andrews","year":"1999","journal-title":"PET and clinical observations. Brain"},{"key":"10.1007\/s13311-013-0244-z_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410400110","article-title":"Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease","volume":"40","author":"Weeks","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib19","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0244-z_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM197302152880703","article-title":"Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain","volume":"288","author":"Perry","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0244-z_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.expneurol.2008.12.015","article-title":"Functional imaging in Huntington's disease","volume":"216","author":"Paulsen","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib22","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1046\/j.1471-4159.2003.01916.x","article-title":"Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6\/2 transgenic mice","volume":"86","author":"Gourfinkel-An","year":"2003","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0244-z_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.0953-816X.2000.01379.x","article-title":"Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6\/1 Huntington transgenic mice","volume":"13","author":"Nicniocaill","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-013-0244-z_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of Huntington's disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet"},{"key":"10.1007\/s13311-013-0244-z_bib25","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin-proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-013-0244-z_bib26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","article-title":"Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy","volume":"11","author":"Ravikumar","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0244-z_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-013-0244-z_bib28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1523\/JNEUROSCI.23-03-00961.2003","article-title":"Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease","volume":"23","author":"Cepeda","year":"2003","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0244-z_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","article-title":"3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin","volume":"18","author":"Ludolph","year":"1991","journal-title":"Can J Neurol Sci"},{"key":"10.1007\/s13311-013-0244-z_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archneur.62.1.46","article-title":"Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways","volume":"62","author":"Gunawardena","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF00194305","article-title":"The epidemiology of Huntington's disease","volume":"89","author":"Harper","year":"1992","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-013-0244-z_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/jmg.32.7.524","article-title":"The epidemiology of Huntington's disease in Northern Ireland","volume":"32","author":"Morrison","year":"1995","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-013-0244-z_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.2008.01110.x","article-title":"Epidemiology of Huntington's disease in Slovenia","volume":"119","author":"Peterlin","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0244-z_bib34","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/mds.22737","article-title":"Clinical and genetic characteristics of Mexican Huntington's disease patients","volume":"24","author":"Alonso","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1192\/bjp.155.6.799","article-title":"The prevalence and patterns of care of Huntington's chorea in Grampian","volume":"155","author":"Simpson","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870050202","article-title":"Huntington's disease in Venezuela: 7\u00a0years of follow-up on symptomatic and asymptomatic individuals","volume":"5","author":"Penney","year":"1990","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib37","series-title":"Huntington's disease","article-title":"The epidemiology of Huntington's disease","author":"Harper","year":"2002"},{"key":"10.1007\/s13311-013-0244-z_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archneur.64.6.813","article-title":"Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients","volume":"64","author":"Ribai","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.30.4.293","article-title":"Suicide risk in Huntington's disease","volume":"30","author":"Di","year":"1993","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-013-0244-z_bib40","unstructured":"Pollard J. Hurry up and wait: a cognitive care companion. 9\/25\/08. XX, Lulu Press, US, 2008. http:\/\/www.lulu.com\/shop\/james-pollard\/hurry-up-and-wait\/paperback\/product-3610588.html#productDetails"},{"key":"10.1007\/s13311-013-0244-z_bib41","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","article-title":"Two years' follow-up of rivastigmine treatment in Huntington disease","volume":"30","author":"de Tommaso","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","article-title":"Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease","volume":"29","author":"Beglinger","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Paulsen Cognitive impairment in Huntington disease: diagnosis and treatment","volume":"11","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-013-0244-z_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2013\/705373","article-title":"The pathophysiology and pharmacological treatment of Huntington disease","volume":"26","author":"Pidgeon","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib46","first-page":"597","article-title":"Miyasaki JM; American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib47","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington's Disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-013-0244-z_bib48","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/0006-2952(83)90388-X","article-title":"Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine","volume":"32","author":"Bagchi","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-013-0244-z_bib50","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington's disease","volume":"23","author":"Phillips","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","article-title":"Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments","volume":"21","author":"Roze","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20071619","article-title":"Huntington's disease: from pathology and genetics to potential therapies","volume":"412","author":"Imarisio","year":"2008","journal-title":"Biochem J"},{"key":"10.1007\/s13311-013-0244-z_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0244-z_bib54","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","article-title":"Treatment of hyperkinetic movement disorders","volume":"8","author":"Jankovic","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib55","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-013-0244-z_bib56","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1007\/s13311-013-0244-z_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1358\/dot.2007.43.2.1050788","article-title":"Huntington's disease: clinical characteristics, pathogenesis and therapies","volume":"43","author":"Nakamura","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1007\/s13311-013-0244-z_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20050148","article-title":"Pharmaceutical, cellular and genetic therapies for Huntington's disease","volume":"110","author":"Handley","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.1007\/s13311-013-0244-z_bib59","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1517\/14656566.5.4.767","article-title":"A review of the treatment options for Huntington's disease","volume":"5","author":"Bonelli","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-013-0244-z_bib60","first-page":"51","article-title":"Therapeutic options for Huntington's disease","volume":"4","author":"Grimbergen","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1007\/s13311-013-0244-z_bib61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/11534430-000000000-00000","article-title":"Advances in the pharmacological management of Huntington's Disease","volume":"70","author":"Frank","year":"2010","journal-title":"Drugs"},{"key":"10.1007\/s13311-013-0244-z_bib62","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-013-0244-z_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0014-2999(84)90563-6","article-title":"Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine","volume":"102","author":"Pettibone","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jps.2600760610","article-title":"Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat","volume":"76","author":"Mehvar","year":"1987","journal-title":"J Pharm Sci"},{"key":"10.1007\/s13311-013-0244-z_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0006-8993(95)00674-F","article-title":"Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine","volume":"692","author":"Thibaut","year":"1995","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0244-z_bib66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Short-term effects of tetrabenazine on chorea associated with Huntington's disease","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0026-895X(25)15021-9","article-title":"Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding","volume":"25","author":"Scherman","year":"1984","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The long-term effect of tetrabenazine in the management of Huntington disease","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib72","first-page":"62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study","volume":"9","author":"Frank","year":"2009","journal-title":"Huntington Study Group\/TETRA-HD Investigators. BMC Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib73","unstructured":"Xenazine. Product information, September 2012. http:\/\/www.lundbeck.com\/upload\/us\/files\/pdf\/Products\/Xenazine_PI_US_EN.pdf"},{"key":"10.1007\/s13311-013-0244-z_bib74","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 genotype and response to tetrabenazine","volume":"28","author":"Mehanna","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib75","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib76","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"10.1007\/s13311-013-0244-z_bib77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A double blind trial of lithium carbonate and haloperidol in Huntington's chorea","volume":"9","author":"Leonard","year":"1975","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.38.1.84","article-title":"Serum haloperidol concentration and choreiform movements in Huntington's disease","volume":"38","author":"Barr","year":"1988","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington's disease: an open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004850-200203000-00009","article-title":"High-dose olanzapine in Huntington's disease","volume":"17","author":"Bonelli","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib81","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington's disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0244-z_bib82","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","article-title":"The use of olanzapine for movement disorder in Huntington's disease: a first case report","volume":"67","author":"Dipple","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib84","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington's disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J Natl Med Assoc."},{"key":"10.1007\/s13311-013-0244-z_bib85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in chorea and psychosis of Huntington's disease","volume":"9","author":"Erdemoglu","year":"2002","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib86","first-page":"347","article-title":"Use of risperidone in psychosis associated with Huntington's disease","volume":"6","author":"Madhusoodanan","year":"1998","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004714-199704000-00023","article-title":"Risperidone in treatment of choreoathetosis of Huntington's disease","volume":"17","author":"Parsa","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1007\/s13311-013-0244-z_bib89","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/070674370404900617","article-title":"Quetiapine in the management of psychosis secondary to Huntington's disease: a case report","volume":"49","author":"Seitz","year":"2004","journal-title":"Can J Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib90","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","article-title":"Quetiapine in Huntington's disease: a first case report","volume":"249","author":"Bonelli","year":"2002","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study","volume":"63","author":"van Vugt","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0244-z_bib92","first-page":"1","article-title":"Aripiprazole in the treatment of Huntington's disease: a case series","volume":"5","author":"Ciammola","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-013-0244-z_bib93","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib94","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/appi.ajp.2008.08040503","article-title":"Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease","volume":"165","author":"Lin","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 2","key":"10.1007\/s13311-013-0244-z_bib95","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s100720200081","article-title":"Amantadine in Huntington's disease: open-label video-blinded study","volume":"23","author":"Lucetti","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-013-0244-z_bib96","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/00007611-198710000-00032","article-title":"Adverse behavioral effects of amantadine therapy in Huntington's disease","volume":"80","author":"Stewart","year":"1987","journal-title":"South Med J"},{"key":"10.1007\/s13311-013-0244-z_bib97","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","author":"Huntington Study Group","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0244-z_bib98","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5694\/j.1326-5377.1976.tb140550.x","article-title":"Clonazepam in the treatment of choreiform activity","volume":"1","author":"Peiris","year":"1976","journal-title":"Med J Aust"},{"key":"10.1007\/s13311-013-0244-z_bib100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(83)90042-4","article-title":"Acute treatment of Huntington's chorea with lisuride","volume":"59","author":"Frattola","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-013-0244-z_bib101","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/mds.21718","article-title":"Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial","volume":"22","author":"Vitale","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0244-z_bib102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1978.00500250031006","article-title":"Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor","volume":"35","author":"Corsini","year":"1978","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5694\/j.1326-5377.1974.tb47770.x","article-title":"Huntington's chorea: the rigid form (Westphal variant) treated with levodopa","volume":"1","author":"Low","year":"1974","journal-title":"Med J Aust"},{"key":"10.1007\/s13311-013-0244-z_bib104","first-page":"45","article-title":"Huntington's chorea\u2014the rigid form (Westphal variant) treated with l-DOPA: a case report","volume":"10","author":"Low","year":"1973","journal-title":"Proc Aust Assoc Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib105","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E004","article-title":"Amantadine in the akinetic-rigid variant of Huntington's disease","volume":"38","author":"Magnet","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1007\/s13311-013-0244-z_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200201000-00011","article-title":"Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0244-z_bib107","first-page":"3","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease","volume":"30","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1007\/s13311-013-0244-z_bib108","first-page":"3","article-title":"An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease","volume":"20","author":"Anderson","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1007\/s13311-013-0244-z_bib109","unstructured":"www.clinicaltrials.gov. Accessed August 9, 2013."},{"key":"10.1007\/s13311-013-0244-z_bib110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2009.334","article-title":"A randomized, placebo-controlled trial of latrepirdine in Huntington disease","volume":"67","author":"Kieburtz","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib111","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study","volume":"65","author":"Huntington Study Group TREND-HD Investigators","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0244-z_bib112","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington's disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0244-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0244-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0244-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:25Z","timestamp":1761808045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1878747923016458"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0244-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Huntington's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0244-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}